Raise closed, search for fresh raises on Seedstage

Salinas, CA

Advancing innovative self-screening technologies to improve global cervical cancer prevention.

• Empowering self-screening: Revolutionizing cervical cancer detection with patented self-administered tools.
• Global accessibility: Addressing screening barriers in underserved regions worldwide.
• Strong market potential: Positioned in a $9.2 billion cervical cancer screening market by 2027.
• Regulatory progress: Achieved CE marking and FDA registration for key products.
• Strategic expansion: Targeting international collaborations in China, India, Brazil, and beyond.

OncoGenesis is revolutionizing cervical cancer prevention with its suite of innovative technologies, including iPap®, Cervi✓©, and the upcoming CerMark® test. These tools empower women globally to self-administer cervical cancer screenings, eliminating traditional barriers to early detection, such as logistical and cultural challenges. With a patented self-collection device, OncoGenesis enables comprehensive screening for both cancer-causing HPV and cervical disease, offering a fast, cost-effective, and accessible solution that has already achieved significant regulatory milestones like CE marking and FDA registration for iPap®.

Funds raised will accelerate product development, secure regulatory approvals, and advance global commercialization efforts, targeting underserved regions with strategic partnerships and distribution channels. With the global cervical cancer screening market projected to reach $9.2 billion by 2027, OncoGenesis is poised to make a significant impact by increasing access to early detection and enabling a see-and-treat approach for cervical cancer prevention.

Company Info

OncoGenesis develops self-administered cervical cancer screening tools to improve early detection and prevention globally.

OncoGenesis Inc. is dedicated to reducing the burden of cervical cancer by making early detection more accessible to women worldwide. The company offers a fast, affordable, and self-administered screening solution, including its iPap® self-collecting device, Cervi✓© kit, and CerMark® rapid test. These technologies enable women to perform cervical cancer screening at home, bypassing the need for clinic visits and making it easier to detect high-risk HPV and cervical disease, including pre-cancer and cancer. This approach is particularly crucial in underserved regions, where cultural and logistical barriers often prevent access to traditional screening methods.

OncoGenesis is poised to impact the $9.2 billion global cervical cancer screening market. The company has achieved significant milestones, including CE marking and FDA registration for its iPap® device, and is working on developing CerMark®, a rapid test that will support the “see and treat” model, allowing for immediate follow-up treatment. With its innovative solutions and strong intellectual property portfolio, OncoGenesis is positioned for global expansion, including partnerships in countries like China, India, Brazil, and Mexico, as well as potential collaborations with NGOs to enhance cervical cancer prevention efforts.